Global Bromhexine

Bromhexine Comprehensive Study by Application (Chronic Bronchitis, Asthma, Cough, Other), Form (Tablets, Syrup), Host (Oral, Injection), Dosage (48 mg/day, 96 mg/day, Others) Players and Region - Global Market Outlook to 2026

Bromhexine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Bromhexine Market Overview:
Bromhexine is a drug that is used in mucolytics problems which breaks the excessive and thick phlegm with a cough. This drug works by allowing direct deposition of drugs that reduces the mucus viscosity in pulmonary health problems and cystic fibrosis. However, it does have some concern over the numerous allergic reactions like an allergic rash, dizziness, and headache.

Growth Drivers
  • Growing Bronchial Problems which Effect the Airways Adversely Requires the Removal of the Mucus
  • Rising Number of Respiratory Problems in People

Market Trends
  • Continuous Research and Development in the Bromhexine Drugs
  • Increasing Popularity of Bromhexine Consumption of Syrup

Roadblocks
  • High Risk of Side Effects and Health-related Issues Like Allergic Rash, Dizziness, etc after the Consumption of Bromhexine Drug

Opportunities
  • Advancements in the Over the Counter Mucolytic Drug and Regulatory Guidelines on the same will Boost the Use of Bromhexine

Challenges
  • Availability of Low-Quality Bromhexine Drug in the Market


Competitive Landscape:

Some of the key players profiled in the report are C.H. Boehringer Sohn AG & Ko. KG (Germany), LGM Pharma (United States), Sigma-Aldrich (United States), Bromhexine (United States), GlaxoSmithKline plc (United Kingdom), Kores Pharmaceutical and Chemicals (India) and Ipca Laboratories Limited (India). Considering Market by Form, the sub-segment i.e. Tablets will boost the Bromhexine market. Considering Market by Host, the sub-segment i.e. Oral will boost the Bromhexine market. Considering Market by Dosage, the sub-segment i.e. 48 mg/day will boost the Bromhexine market.

"A regulatory body representing EU Member States – has endorsed recommendations to add information about a small risk of severe allergic reactions, including severe cutaneous adverse reactions (SCARs) such as and erythema multiforme and Stevens Johnson syndrome, to the product information for ambroxol- and bromhexine containing medicines, which are widely used in the EU as expectorants."

What Can be Explored with the Bromhexine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Bromhexine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Bromhexine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Bromhexine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Bromhexine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Bromhexine Manufacturers, Bromhexine International Traders, Bromhexine Distributors and Suppliers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Chronic Bronchitis
  • Asthma
  • Cough
  • Other
By Form
  • Tablets
  • Syrup

By Host
  • Oral
  • Injection

By Dosage
  • 48 mg/day
  • 96 mg/day
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Bronchial Problems which Effect the Airways Adversely Requires the Removal of the Mucus
      • 3.2.2. Rising Number of Respiratory Problems in People
    • 3.3. Market Challenges
      • 3.3.1. Availability of Low-Quality Bromhexine Drug in the Market
    • 3.4. Market Trends
      • 3.4.1. Continuous Research and Development in the Bromhexine Drugs
      • 3.4.2. Increasing Popularity of Bromhexine Consumption of Syrup
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bromhexine, by Application, Form, Host, Dosage and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Bromhexine (Value)
      • 5.2.1. Global Bromhexine by: Application (Value)
        • 5.2.1.1. Chronic Bronchitis
        • 5.2.1.2. Asthma
        • 5.2.1.3. Cough
        • 5.2.1.4. Other
      • 5.2.2. Global Bromhexine by: Form (Value)
        • 5.2.2.1. Tablets
        • 5.2.2.2. Syrup
      • 5.2.3. Global Bromhexine by: Host (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injection
      • 5.2.4. Global Bromhexine by: Dosage (Value)
        • 5.2.4.1. 48 mg/day
        • 5.2.4.2. 96 mg/day
        • 5.2.4.3. Others
      • 5.2.5. Global Bromhexine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Bromhexine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. C.H. Boehringer Sohn AG & Ko. KG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. LGM Pharma (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sigma-Aldrich (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bromhexine (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kores Pharmaceutical and Chemicals (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ipca Laboratories Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Bromhexine Sale, by Application, Form, Host, Dosage and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Bromhexine (Value)
      • 7.2.1. Global Bromhexine by: Application (Value)
        • 7.2.1.1. Chronic Bronchitis
        • 7.2.1.2. Asthma
        • 7.2.1.3. Cough
        • 7.2.1.4. Other
      • 7.2.2. Global Bromhexine by: Form (Value)
        • 7.2.2.1. Tablets
        • 7.2.2.2. Syrup
      • 7.2.3. Global Bromhexine by: Host (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injection
      • 7.2.4. Global Bromhexine by: Dosage (Value)
        • 7.2.4.1. 48 mg/day
        • 7.2.4.2. 96 mg/day
        • 7.2.4.3. Others
      • 7.2.5. Global Bromhexine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bromhexine: by Application(USD Million)
  • Table 2. Bromhexine Chronic Bronchitis , by Region USD Million (2015-2020)
  • Table 3. Bromhexine Asthma , by Region USD Million (2015-2020)
  • Table 4. Bromhexine Cough , by Region USD Million (2015-2020)
  • Table 5. Bromhexine Other , by Region USD Million (2015-2020)
  • Table 6. Bromhexine: by Form(USD Million)
  • Table 7. Bromhexine Tablets , by Region USD Million (2015-2020)
  • Table 8. Bromhexine Syrup , by Region USD Million (2015-2020)
  • Table 9. Bromhexine: by Host(USD Million)
  • Table 10. Bromhexine Oral , by Region USD Million (2015-2020)
  • Table 11. Bromhexine Injection , by Region USD Million (2015-2020)
  • Table 12. Bromhexine: by Dosage(USD Million)
  • Table 13. Bromhexine 48 mg/day , by Region USD Million (2015-2020)
  • Table 14. Bromhexine 96 mg/day , by Region USD Million (2015-2020)
  • Table 15. Bromhexine Others , by Region USD Million (2015-2020)
  • Table 16. South America Bromhexine, by Country USD Million (2015-2020)
  • Table 17. South America Bromhexine, by Application USD Million (2015-2020)
  • Table 18. South America Bromhexine, by Form USD Million (2015-2020)
  • Table 19. South America Bromhexine, by Host USD Million (2015-2020)
  • Table 20. South America Bromhexine, by Dosage USD Million (2015-2020)
  • Table 21. Brazil Bromhexine, by Application USD Million (2015-2020)
  • Table 22. Brazil Bromhexine, by Form USD Million (2015-2020)
  • Table 23. Brazil Bromhexine, by Host USD Million (2015-2020)
  • Table 24. Brazil Bromhexine, by Dosage USD Million (2015-2020)
  • Table 25. Argentina Bromhexine, by Application USD Million (2015-2020)
  • Table 26. Argentina Bromhexine, by Form USD Million (2015-2020)
  • Table 27. Argentina Bromhexine, by Host USD Million (2015-2020)
  • Table 28. Argentina Bromhexine, by Dosage USD Million (2015-2020)
  • Table 29. Rest of South America Bromhexine, by Application USD Million (2015-2020)
  • Table 30. Rest of South America Bromhexine, by Form USD Million (2015-2020)
  • Table 31. Rest of South America Bromhexine, by Host USD Million (2015-2020)
  • Table 32. Rest of South America Bromhexine, by Dosage USD Million (2015-2020)
  • Table 33. Asia Pacific Bromhexine, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Bromhexine, by Application USD Million (2015-2020)
  • Table 35. Asia Pacific Bromhexine, by Form USD Million (2015-2020)
  • Table 36. Asia Pacific Bromhexine, by Host USD Million (2015-2020)
  • Table 37. Asia Pacific Bromhexine, by Dosage USD Million (2015-2020)
  • Table 38. China Bromhexine, by Application USD Million (2015-2020)
  • Table 39. China Bromhexine, by Form USD Million (2015-2020)
  • Table 40. China Bromhexine, by Host USD Million (2015-2020)
  • Table 41. China Bromhexine, by Dosage USD Million (2015-2020)
  • Table 42. Japan Bromhexine, by Application USD Million (2015-2020)
  • Table 43. Japan Bromhexine, by Form USD Million (2015-2020)
  • Table 44. Japan Bromhexine, by Host USD Million (2015-2020)
  • Table 45. Japan Bromhexine, by Dosage USD Million (2015-2020)
  • Table 46. India Bromhexine, by Application USD Million (2015-2020)
  • Table 47. India Bromhexine, by Form USD Million (2015-2020)
  • Table 48. India Bromhexine, by Host USD Million (2015-2020)
  • Table 49. India Bromhexine, by Dosage USD Million (2015-2020)
  • Table 50. South Korea Bromhexine, by Application USD Million (2015-2020)
  • Table 51. South Korea Bromhexine, by Form USD Million (2015-2020)
  • Table 52. South Korea Bromhexine, by Host USD Million (2015-2020)
  • Table 53. South Korea Bromhexine, by Dosage USD Million (2015-2020)
  • Table 54. Taiwan Bromhexine, by Application USD Million (2015-2020)
  • Table 55. Taiwan Bromhexine, by Form USD Million (2015-2020)
  • Table 56. Taiwan Bromhexine, by Host USD Million (2015-2020)
  • Table 57. Taiwan Bromhexine, by Dosage USD Million (2015-2020)
  • Table 58. Australia Bromhexine, by Application USD Million (2015-2020)
  • Table 59. Australia Bromhexine, by Form USD Million (2015-2020)
  • Table 60. Australia Bromhexine, by Host USD Million (2015-2020)
  • Table 61. Australia Bromhexine, by Dosage USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Bromhexine, by Application USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Bromhexine, by Form USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Bromhexine, by Host USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Bromhexine, by Dosage USD Million (2015-2020)
  • Table 66. Europe Bromhexine, by Country USD Million (2015-2020)
  • Table 67. Europe Bromhexine, by Application USD Million (2015-2020)
  • Table 68. Europe Bromhexine, by Form USD Million (2015-2020)
  • Table 69. Europe Bromhexine, by Host USD Million (2015-2020)
  • Table 70. Europe Bromhexine, by Dosage USD Million (2015-2020)
  • Table 71. Germany Bromhexine, by Application USD Million (2015-2020)
  • Table 72. Germany Bromhexine, by Form USD Million (2015-2020)
  • Table 73. Germany Bromhexine, by Host USD Million (2015-2020)
  • Table 74. Germany Bromhexine, by Dosage USD Million (2015-2020)
  • Table 75. France Bromhexine, by Application USD Million (2015-2020)
  • Table 76. France Bromhexine, by Form USD Million (2015-2020)
  • Table 77. France Bromhexine, by Host USD Million (2015-2020)
  • Table 78. France Bromhexine, by Dosage USD Million (2015-2020)
  • Table 79. Italy Bromhexine, by Application USD Million (2015-2020)
  • Table 80. Italy Bromhexine, by Form USD Million (2015-2020)
  • Table 81. Italy Bromhexine, by Host USD Million (2015-2020)
  • Table 82. Italy Bromhexine, by Dosage USD Million (2015-2020)
  • Table 83. United Kingdom Bromhexine, by Application USD Million (2015-2020)
  • Table 84. United Kingdom Bromhexine, by Form USD Million (2015-2020)
  • Table 85. United Kingdom Bromhexine, by Host USD Million (2015-2020)
  • Table 86. United Kingdom Bromhexine, by Dosage USD Million (2015-2020)
  • Table 87. Netherlands Bromhexine, by Application USD Million (2015-2020)
  • Table 88. Netherlands Bromhexine, by Form USD Million (2015-2020)
  • Table 89. Netherlands Bromhexine, by Host USD Million (2015-2020)
  • Table 90. Netherlands Bromhexine, by Dosage USD Million (2015-2020)
  • Table 91. Rest of Europe Bromhexine, by Application USD Million (2015-2020)
  • Table 92. Rest of Europe Bromhexine, by Form USD Million (2015-2020)
  • Table 93. Rest of Europe Bromhexine, by Host USD Million (2015-2020)
  • Table 94. Rest of Europe Bromhexine, by Dosage USD Million (2015-2020)
  • Table 95. MEA Bromhexine, by Country USD Million (2015-2020)
  • Table 96. MEA Bromhexine, by Application USD Million (2015-2020)
  • Table 97. MEA Bromhexine, by Form USD Million (2015-2020)
  • Table 98. MEA Bromhexine, by Host USD Million (2015-2020)
  • Table 99. MEA Bromhexine, by Dosage USD Million (2015-2020)
  • Table 100. Middle East Bromhexine, by Application USD Million (2015-2020)
  • Table 101. Middle East Bromhexine, by Form USD Million (2015-2020)
  • Table 102. Middle East Bromhexine, by Host USD Million (2015-2020)
  • Table 103. Middle East Bromhexine, by Dosage USD Million (2015-2020)
  • Table 104. Africa Bromhexine, by Application USD Million (2015-2020)
  • Table 105. Africa Bromhexine, by Form USD Million (2015-2020)
  • Table 106. Africa Bromhexine, by Host USD Million (2015-2020)
  • Table 107. Africa Bromhexine, by Dosage USD Million (2015-2020)
  • Table 108. North America Bromhexine, by Country USD Million (2015-2020)
  • Table 109. North America Bromhexine, by Application USD Million (2015-2020)
  • Table 110. North America Bromhexine, by Form USD Million (2015-2020)
  • Table 111. North America Bromhexine, by Host USD Million (2015-2020)
  • Table 112. North America Bromhexine, by Dosage USD Million (2015-2020)
  • Table 113. United States Bromhexine, by Application USD Million (2015-2020)
  • Table 114. United States Bromhexine, by Form USD Million (2015-2020)
  • Table 115. United States Bromhexine, by Host USD Million (2015-2020)
  • Table 116. United States Bromhexine, by Dosage USD Million (2015-2020)
  • Table 117. Canada Bromhexine, by Application USD Million (2015-2020)
  • Table 118. Canada Bromhexine, by Form USD Million (2015-2020)
  • Table 119. Canada Bromhexine, by Host USD Million (2015-2020)
  • Table 120. Canada Bromhexine, by Dosage USD Million (2015-2020)
  • Table 121. Mexico Bromhexine, by Application USD Million (2015-2020)
  • Table 122. Mexico Bromhexine, by Form USD Million (2015-2020)
  • Table 123. Mexico Bromhexine, by Host USD Million (2015-2020)
  • Table 124. Mexico Bromhexine, by Dosage USD Million (2015-2020)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Bromhexine: by Application(USD Million)
  • Table 133. Bromhexine Chronic Bronchitis , by Region USD Million (2021-2026)
  • Table 134. Bromhexine Asthma , by Region USD Million (2021-2026)
  • Table 135. Bromhexine Cough , by Region USD Million (2021-2026)
  • Table 136. Bromhexine Other , by Region USD Million (2021-2026)
  • Table 137. Bromhexine: by Form(USD Million)
  • Table 138. Bromhexine Tablets , by Region USD Million (2021-2026)
  • Table 139. Bromhexine Syrup , by Region USD Million (2021-2026)
  • Table 140. Bromhexine: by Host(USD Million)
  • Table 141. Bromhexine Oral , by Region USD Million (2021-2026)
  • Table 142. Bromhexine Injection , by Region USD Million (2021-2026)
  • Table 143. Bromhexine: by Dosage(USD Million)
  • Table 144. Bromhexine 48 mg/day , by Region USD Million (2021-2026)
  • Table 145. Bromhexine 96 mg/day , by Region USD Million (2021-2026)
  • Table 146. Bromhexine Others , by Region USD Million (2021-2026)
  • Table 147. South America Bromhexine, by Country USD Million (2021-2026)
  • Table 148. South America Bromhexine, by Application USD Million (2021-2026)
  • Table 149. South America Bromhexine, by Form USD Million (2021-2026)
  • Table 150. South America Bromhexine, by Host USD Million (2021-2026)
  • Table 151. South America Bromhexine, by Dosage USD Million (2021-2026)
  • Table 152. Brazil Bromhexine, by Application USD Million (2021-2026)
  • Table 153. Brazil Bromhexine, by Form USD Million (2021-2026)
  • Table 154. Brazil Bromhexine, by Host USD Million (2021-2026)
  • Table 155. Brazil Bromhexine, by Dosage USD Million (2021-2026)
  • Table 156. Argentina Bromhexine, by Application USD Million (2021-2026)
  • Table 157. Argentina Bromhexine, by Form USD Million (2021-2026)
  • Table 158. Argentina Bromhexine, by Host USD Million (2021-2026)
  • Table 159. Argentina Bromhexine, by Dosage USD Million (2021-2026)
  • Table 160. Rest of South America Bromhexine, by Application USD Million (2021-2026)
  • Table 161. Rest of South America Bromhexine, by Form USD Million (2021-2026)
  • Table 162. Rest of South America Bromhexine, by Host USD Million (2021-2026)
  • Table 163. Rest of South America Bromhexine, by Dosage USD Million (2021-2026)
  • Table 164. Asia Pacific Bromhexine, by Country USD Million (2021-2026)
  • Table 165. Asia Pacific Bromhexine, by Application USD Million (2021-2026)
  • Table 166. Asia Pacific Bromhexine, by Form USD Million (2021-2026)
  • Table 167. Asia Pacific Bromhexine, by Host USD Million (2021-2026)
  • Table 168. Asia Pacific Bromhexine, by Dosage USD Million (2021-2026)
  • Table 169. China Bromhexine, by Application USD Million (2021-2026)
  • Table 170. China Bromhexine, by Form USD Million (2021-2026)
  • Table 171. China Bromhexine, by Host USD Million (2021-2026)
  • Table 172. China Bromhexine, by Dosage USD Million (2021-2026)
  • Table 173. Japan Bromhexine, by Application USD Million (2021-2026)
  • Table 174. Japan Bromhexine, by Form USD Million (2021-2026)
  • Table 175. Japan Bromhexine, by Host USD Million (2021-2026)
  • Table 176. Japan Bromhexine, by Dosage USD Million (2021-2026)
  • Table 177. India Bromhexine, by Application USD Million (2021-2026)
  • Table 178. India Bromhexine, by Form USD Million (2021-2026)
  • Table 179. India Bromhexine, by Host USD Million (2021-2026)
  • Table 180. India Bromhexine, by Dosage USD Million (2021-2026)
  • Table 181. South Korea Bromhexine, by Application USD Million (2021-2026)
  • Table 182. South Korea Bromhexine, by Form USD Million (2021-2026)
  • Table 183. South Korea Bromhexine, by Host USD Million (2021-2026)
  • Table 184. South Korea Bromhexine, by Dosage USD Million (2021-2026)
  • Table 185. Taiwan Bromhexine, by Application USD Million (2021-2026)
  • Table 186. Taiwan Bromhexine, by Form USD Million (2021-2026)
  • Table 187. Taiwan Bromhexine, by Host USD Million (2021-2026)
  • Table 188. Taiwan Bromhexine, by Dosage USD Million (2021-2026)
  • Table 189. Australia Bromhexine, by Application USD Million (2021-2026)
  • Table 190. Australia Bromhexine, by Form USD Million (2021-2026)
  • Table 191. Australia Bromhexine, by Host USD Million (2021-2026)
  • Table 192. Australia Bromhexine, by Dosage USD Million (2021-2026)
  • Table 193. Rest of Asia-Pacific Bromhexine, by Application USD Million (2021-2026)
  • Table 194. Rest of Asia-Pacific Bromhexine, by Form USD Million (2021-2026)
  • Table 195. Rest of Asia-Pacific Bromhexine, by Host USD Million (2021-2026)
  • Table 196. Rest of Asia-Pacific Bromhexine, by Dosage USD Million (2021-2026)
  • Table 197. Europe Bromhexine, by Country USD Million (2021-2026)
  • Table 198. Europe Bromhexine, by Application USD Million (2021-2026)
  • Table 199. Europe Bromhexine, by Form USD Million (2021-2026)
  • Table 200. Europe Bromhexine, by Host USD Million (2021-2026)
  • Table 201. Europe Bromhexine, by Dosage USD Million (2021-2026)
  • Table 202. Germany Bromhexine, by Application USD Million (2021-2026)
  • Table 203. Germany Bromhexine, by Form USD Million (2021-2026)
  • Table 204. Germany Bromhexine, by Host USD Million (2021-2026)
  • Table 205. Germany Bromhexine, by Dosage USD Million (2021-2026)
  • Table 206. France Bromhexine, by Application USD Million (2021-2026)
  • Table 207. France Bromhexine, by Form USD Million (2021-2026)
  • Table 208. France Bromhexine, by Host USD Million (2021-2026)
  • Table 209. France Bromhexine, by Dosage USD Million (2021-2026)
  • Table 210. Italy Bromhexine, by Application USD Million (2021-2026)
  • Table 211. Italy Bromhexine, by Form USD Million (2021-2026)
  • Table 212. Italy Bromhexine, by Host USD Million (2021-2026)
  • Table 213. Italy Bromhexine, by Dosage USD Million (2021-2026)
  • Table 214. United Kingdom Bromhexine, by Application USD Million (2021-2026)
  • Table 215. United Kingdom Bromhexine, by Form USD Million (2021-2026)
  • Table 216. United Kingdom Bromhexine, by Host USD Million (2021-2026)
  • Table 217. United Kingdom Bromhexine, by Dosage USD Million (2021-2026)
  • Table 218. Netherlands Bromhexine, by Application USD Million (2021-2026)
  • Table 219. Netherlands Bromhexine, by Form USD Million (2021-2026)
  • Table 220. Netherlands Bromhexine, by Host USD Million (2021-2026)
  • Table 221. Netherlands Bromhexine, by Dosage USD Million (2021-2026)
  • Table 222. Rest of Europe Bromhexine, by Application USD Million (2021-2026)
  • Table 223. Rest of Europe Bromhexine, by Form USD Million (2021-2026)
  • Table 224. Rest of Europe Bromhexine, by Host USD Million (2021-2026)
  • Table 225. Rest of Europe Bromhexine, by Dosage USD Million (2021-2026)
  • Table 226. MEA Bromhexine, by Country USD Million (2021-2026)
  • Table 227. MEA Bromhexine, by Application USD Million (2021-2026)
  • Table 228. MEA Bromhexine, by Form USD Million (2021-2026)
  • Table 229. MEA Bromhexine, by Host USD Million (2021-2026)
  • Table 230. MEA Bromhexine, by Dosage USD Million (2021-2026)
  • Table 231. Middle East Bromhexine, by Application USD Million (2021-2026)
  • Table 232. Middle East Bromhexine, by Form USD Million (2021-2026)
  • Table 233. Middle East Bromhexine, by Host USD Million (2021-2026)
  • Table 234. Middle East Bromhexine, by Dosage USD Million (2021-2026)
  • Table 235. Africa Bromhexine, by Application USD Million (2021-2026)
  • Table 236. Africa Bromhexine, by Form USD Million (2021-2026)
  • Table 237. Africa Bromhexine, by Host USD Million (2021-2026)
  • Table 238. Africa Bromhexine, by Dosage USD Million (2021-2026)
  • Table 239. North America Bromhexine, by Country USD Million (2021-2026)
  • Table 240. North America Bromhexine, by Application USD Million (2021-2026)
  • Table 241. North America Bromhexine, by Form USD Million (2021-2026)
  • Table 242. North America Bromhexine, by Host USD Million (2021-2026)
  • Table 243. North America Bromhexine, by Dosage USD Million (2021-2026)
  • Table 244. United States Bromhexine, by Application USD Million (2021-2026)
  • Table 245. United States Bromhexine, by Form USD Million (2021-2026)
  • Table 246. United States Bromhexine, by Host USD Million (2021-2026)
  • Table 247. United States Bromhexine, by Dosage USD Million (2021-2026)
  • Table 248. Canada Bromhexine, by Application USD Million (2021-2026)
  • Table 249. Canada Bromhexine, by Form USD Million (2021-2026)
  • Table 250. Canada Bromhexine, by Host USD Million (2021-2026)
  • Table 251. Canada Bromhexine, by Dosage USD Million (2021-2026)
  • Table 252. Mexico Bromhexine, by Application USD Million (2021-2026)
  • Table 253. Mexico Bromhexine, by Form USD Million (2021-2026)
  • Table 254. Mexico Bromhexine, by Host USD Million (2021-2026)
  • Table 255. Mexico Bromhexine, by Dosage USD Million (2021-2026)
  • Table 256. Research Programs/Design for This Report
  • Table 257. Key Data Information from Secondary Sources
  • Table 258. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bromhexine: by Application USD Million (2015-2020)
  • Figure 5. Global Bromhexine: by Form USD Million (2015-2020)
  • Figure 6. Global Bromhexine: by Host USD Million (2015-2020)
  • Figure 7. Global Bromhexine: by Dosage USD Million (2015-2020)
  • Figure 8. South America Bromhexine Share (%), by Country
  • Figure 9. Asia Pacific Bromhexine Share (%), by Country
  • Figure 10. Europe Bromhexine Share (%), by Country
  • Figure 11. MEA Bromhexine Share (%), by Country
  • Figure 12. North America Bromhexine Share (%), by Country
  • Figure 13. Global Bromhexine share by Players 2020 (%)
  • Figure 14. Global Bromhexine share by Players (Top 3) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 17. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2020
  • Figure 18. LGM Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 19. LGM Pharma (United States) Revenue: by Geography 2020
  • Figure 20. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 21. Sigma-Aldrich (United States) Revenue: by Geography 2020
  • Figure 22. Bromhexine (United States) Revenue, Net Income and Gross profit
  • Figure 23. Bromhexine (United States) Revenue: by Geography 2020
  • Figure 24. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 25. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 26. Kores Pharmaceutical and Chemicals (India) Revenue, Net Income and Gross profit
  • Figure 27. Kores Pharmaceutical and Chemicals (India) Revenue: by Geography 2020
  • Figure 28. Ipca Laboratories Limited (India) Revenue, Net Income and Gross profit
  • Figure 29. Ipca Laboratories Limited (India) Revenue: by Geography 2020
  • Figure 30. Global Bromhexine: by Application USD Million (2021-2026)
  • Figure 31. Global Bromhexine: by Form USD Million (2021-2026)
  • Figure 32. Global Bromhexine: by Host USD Million (2021-2026)
  • Figure 33. Global Bromhexine: by Dosage USD Million (2021-2026)
  • Figure 34. South America Bromhexine Share (%), by Country
  • Figure 35. Asia Pacific Bromhexine Share (%), by Country
  • Figure 36. Europe Bromhexine Share (%), by Country
  • Figure 37. MEA Bromhexine Share (%), by Country
  • Figure 38. North America Bromhexine Share (%), by Country
List of companies from research coverage that are profiled in the study
  • C.H. Boehringer Sohn AG & Ko. KG (Germany)
  • LGM Pharma (United States)
  • Sigma-Aldrich (United States)
  • Bromhexine (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Kores Pharmaceutical and Chemicals (India)
  • Ipca Laboratories Limited (India)
Select User Access Type

Key Highlights of Report


Feb 2021 236 Pages 68 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bromhexine Quantitative research analysis
Global Bromhexine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Bromhexine Report?

Have a Query? Click Here

Other Related Reports

Metastatic Ovarian Cancer Drug Comprehensive Study by Type (E-7449, Crizotinib, CMB-305, G-305, LV-305, Others), Application (Clinic, Hospital, Others), Ovarian Cancer (Epithelial Ovarian Cancer, Str...
$ 3350
Levothyroxine Comprehensive Study by Type (Tablet, Intravenous Injection), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Players and Region - Global Market Outlook to 203...
$ 3500
MEM Media Comprehensive Study by Application (Liquid, Powder), Disease (Schizophrenia, Migraine, Opioid dependence, Nausea, Vomiting, Others), Distribution Channel (Online, Offline), Component (L-glu...
$ 3350
Codeine Comprehensive Study by Type (Extracted from Opium, Synthesized by Morphine), Application (Pain Management, Cough Treatment, Diarrhea Treatment), Forms (Tablets, Capsules, Suppositories, Solub...
$ 3650
Pharmaceutical Excipients Comprehensive Study by Type (Inorganic Chemicals {Calcium Phosphates, Calcium Carbonate, Calcium Sulfate, Halites and Metallic Oxides}, Organic Chemicals {Carbohydrates (Sug...
$ 3750
Hyperimmune Globulins Comprehensive Study by Type (Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins, Others), Application (Government Institutions, Private Sector, Others)...
$ 3650